The company's revenue rose eight percent during the quarter, to almost $15.3 billion, primarily driven by growth in oncology and rare diseases, the company said.
This comes at the same time that the operating profit for the company's core business increased by twelve percent.
“We continue to invest in our commercial capabilities as we prepare for multiple launches, look forward to further results expected throughout the year, and remain on track to achieve our ambition for 2030 and beyond,” CEO Pascal Soriot said in the report.
